AstraZeneca stock closed up 1.6%, at 31.80 ... In first-line ovarian …
ovarian cancer
Genentech, and Novartis. Thesis, Time Frame For Outperformance, and Risks: For investors who've done their due diligence and are interested in the story, I suggest buying shares in the near term. The stock price is near …
Shares
The comprehensive failure prompted Xenon to admit the data don’t support continued development of XEN801 and wiped 44% off its stock price in …
Xenon
Today, Biogen (NASDAQ:BIIB) stock was downgraded by Morgan Stanley from Overweight ... It also has a …
Morgan Stanley
The stock gained 11.2% compared to the Large Cap Pharmaceuticals ... vulgaris remission rates and successful tapering and/or cessation of CS therapy. Also, Genentech is currently enrolling in a phase III study in …
Rituxan
Illumina stock isn't cheap. Shares currently trade at a whopping ... gaining U.S. regulatory approval in 1998. The company's Genentech Research …
Illumina
Triggers for re-rating of the stock include Glargine, Humira and GCSF filings in next few quarters. Morgan Stanley is overweight on Biocon with a …
target price
Genentech Inc. stock will stop being traded at the end of today’s trading day — the end of an era for the Bay Area’s biotech giant — after Swiss drug giant Roche completed its $95-a-share tender offer for Genentech
Genentech